SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2003

                           Introgen Therapeutics, Inc.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

     Delaware                           0-21291                  74-2704230
--------------------------------------------------------------------------------
(State or other jurisdiction          (Commission              (IRS Employer
of incorporation)                     File Number)           Identification No.)

            301 Congress Avenue, Suite 1850, Austin, Texas         78701
--------------------------------------------------------------------------------
              (Address of principal executive offices)           (Zip Code)

Registrant's telephone number, including area code: (512) 708-9310

--------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)




Item 7. Financial Statements and Exhibits.

      (c)   Exhibits.

      99.1  Press Release dated November 12, 2003.

Item 12. Results of Operations and Financial Condition.

      Attached hereto as Exhibit 99.1 and  incorporated  by reference  herein is
the text of the registrant's press release,  dated November 12, 2003,  regarding
results of operations and financial  condition for the registrant's third fiscal
quarter ended September 30, 2003.

      The  information in this Current Report on Form 8-K is being furnished and
shall not be deemed  "filed" for the  purposes  of Section 18 of the  Securities
Exchange Act of 1934, as amended,  or otherwise  subject to the  liabilities  of
that Section.

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Dated: November 12, 2003                           INTROGEN THERAPEUTICS, INC.

                                            /s/ James W. Albrecht, Jr.
                                            ------------------------------------
                                            James W. Albrecht, Jr.
                                            Chief Financial Officer


                                      -2-


                                INDEX TO EXHIBITS

Exhibit
Number            Description of Document
------            -----------------------

99.1              Press Release dated November 12, 2003.